Fasenra

Chemical Namebenralizumab
Dosage FormInjectable (subcutaneous; 30 mg/mL)
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyAstraZeneca
Approval Year2017

Indication

  • Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Last updated on 2/3/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Fasenra (benralizumab) Prescribing Information 2019AstraZeneca